unusedbrandon-bourdages-shutterstock-com-us-supreme-court--1
Brandon Bourdages / Shutterstock.com
17 February 2016Americas

Sandoz appeals to US Supreme Court over ‘patent dance’ ruling

Sandoz has petitioned the US Supreme Court to review the US Court of Appeals for the Federal Circuit’s ruling in the ‘patent dance’ dispute.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
19 October 2015   The US Court of Appeals for the Federal Circuit has declined to hear the Amgen v Sandoz ‘patent dance’ dispute en banc.
Americas
22 July 2015   The US Court of Appeals for the Federal Circuit has ruled that biosimilar applicants can opt out of the so-called patent dance, paving the way for Sandoz to sell a biosimilar version of an Amgen drug.

More on this story

Americas
19 October 2015   The US Court of Appeals for the Federal Circuit has declined to hear the Amgen v Sandoz ‘patent dance’ dispute en banc.
Americas
22 July 2015   The US Court of Appeals for the Federal Circuit has ruled that biosimilar applicants can opt out of the so-called patent dance, paving the way for Sandoz to sell a biosimilar version of an Amgen drug.

More on this story

Americas
19 October 2015   The US Court of Appeals for the Federal Circuit has declined to hear the Amgen v Sandoz ‘patent dance’ dispute en banc.
Americas
22 July 2015   The US Court of Appeals for the Federal Circuit has ruled that biosimilar applicants can opt out of the so-called patent dance, paving the way for Sandoz to sell a biosimilar version of an Amgen drug.